Nodom (Dorzolamide Hydrochloride)

Dorzolamide Hydrochloride, the active ingredient in Nodom, is a carbonic anhydrase inhibitor presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is used to treat open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Nodom as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions. Customers benefit from reliable lead times and comprehensive technical support throughout the procurement process.

Dorzolamide Hydrochloride is indicated for ocular conditions where reduction of intra‑ocular pressure is required. - Open‑angle glaucoma: lowers intra‑ocular pressure to help prevent optic nerve damage. - Ocular hypertension: reduces elevated eye pressure to decrease risk of progression to glaucoma. - Secondary glaucoma (adjunct therapy): contributes to pressure control when used with other antiglaucoma agents.

Topical dorzolamide may cause ocular and systemic adverse reactions, most of which are mild and transient.

Common Side Effects: - Blurred vision: temporary difficulty focusing after instillation. - Eye irritation: burning or stinging sensation. - Bitter taste: metallic taste after drainage through the nasolacrimal duct.

Serious or Rare Side Effects: - Allergic reaction: swelling, rash, or itching around the eye. - Severe eye pain: may indicate corneal edema. - Stevens‑Johnson syndrome: rare systemic skin reaction.

When prescribing dorzolamide eye drops, clinicians should consider several safety measures to minimize risks. - Monitor intra‑ocular pressure: schedule regular IOP assessments. - Assess sulfonamide allergy: avoid use in patients with known sulfa hypersensitivity. - Remove contact lenses: advise patients to take out lenses before instillation. - Avoid concurrent carbonic anhydrase inhibitors: risk of excessive pressure reduction. - Store at room temperature: keep in the original container, protect from light and moisture.

Dorzolamide can interact with other ophthalmic or systemic agents, affecting efficacy or safety.

Major Interactions (Avoid): - Concurrent use of other topical carbonic anhydrase inhibitors: may cause excessive intra‑ocular pressure lowering. - Systemic sulfonamide drugs in sulfa‑allergic patients: increase risk of hypersensitivity reactions.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive IOP‑lowering effect, monitor pressure. - Prostaglandin analogues: combined therapy may require IOP monitoring. - Oral carbonic anhydrase inhibitors (e.g., acetazolamide): may increase systemic exposure and side effects.